Navigation Links
ULURU Inc. Reports Third Quarter 2013 Financial Results
Date:11/15/2013

and licensing fees which were partially offset by a decrease of $50,000 in royalties related to the domestic sale of Aphthasol®, as a result of the patent expiration and resulting license termination.

Research and Development
Research and development expenses were $201,000 for the third quarter of 2013, including $5,000 in share-based compensation, as compared to $153,000 for the third quarter 2012, which included no share-based compensation. The increase of approximately $48,000 in research and development expenses was entirely due to an increase of $54,000 in personnel expense.

Research and development expenses were $578,000 for the nine months ended September 30, 2013, including $12,000 in share-based compensation, as compared to $517,000 for the nine months ended September 30, 2012, which included $9,000 in share-based compensation. The increase of approximately $61,000 in research and development expenses was primarily due to an increase of $85,000 in personnel expense which was partially offset by a decrease of $20,000 in clinical study costs.

Selling, General and Administrative
Selling, general and administrative expenses were $302,000 for the third quarter of 2013, including $20,000 in share-based compensation, as compared to $376,000 for the third quarter of 2012, which included $8,000 in share-based compensation. The decrease of approximately $74,000 in selling, general and administrative expenses was primarily due to a decrease of $109,000 in sales & marketing costs due to a revised sales and marketing plan and a lower head count, and a decrease of $20,000 related to accruals for bad debt expense. These expense decreases were partially offset by an increase of $35,000 in investor relations consulting and an increase of $11,000 in director fees.

Selling, general and administrative expenses were $915,000 for the nine months ended September 30, 2013, including $45,000 in share-based compe
'/>"/>

SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Third Quarter Ended September 30, 2013
2. ULURU Inc. Completes Redemption Of Preferred Stock
3. ULURU Inc. Reports Second Quarter 2013 Financial Results
4. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
5. ULURU Inc. Reports First Quarter 2013 Financial Results
6. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
7. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
9. ULURU Inc. Business Update And Outlook
10. ULURU Inc. Announces Closing Of $440,000 Private Placement
11. ULURU Inc. Reports Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ today ... the commercial development of the company,s supplemental oxygen ... Oxygen device, being developed by ieCrowd,s subsidiary Smart ... patient,s changing demand for oxygen based on level ... (k) submission for the Smart Oxygen device would ...
(Date:8/27/2015)... Lilly and Company (NYSE: LLY ) will attend ... 17, 2015. Sue Mahony , Ph.D., senior vice ... Gaynor , M.D., senior vice president of product development ... a fireside chat at 3:30 p.m., Eastern Daylight Time. ... available on the "Webcasts & Presentations" section of Lilly,s ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Be Useful in Cancer Treatment,Decisions , SALT LAKE ... (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced today that,it presented ... used to,determine the original location of a metastatic ... meeting of the American Association,for Cancer Research (AACR) ...
... WIRE)--Apr 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) ... results from the Phase III clinical trial,evaluating ... ALTACE(R),(ramipril) diuretic fixed-dose combination product. The Company ... expects to present the,findings in detail at ...
Cached Medicine Technology:Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and ... neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor ... to earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... 28, 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, was ... for a good cause. In its second year, the “Music With A Mission” benefit ... Rehabilitation. The “Mission” of “Music With A Mission” is to raise money to help ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... evaluations for those seeking to go deep sea diving. The act of ... and decompression sickness; for these reasons, it is vital that all recreational and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan ... general use any time soon, according to educational website Surviving Mesothelioma. Click here ... orphan drug designation for mesothelioma last week from the FDA, will now head into ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2
... VSCP ), a leading provider of quantitative ... exceeds $27 million,compared to $14.7 million at the same ... company calculates backlog as the amount remaining to be,recognized ... studies,included within the backlog ranges from 2 months to ...
... nationally recognized Consumer Watchdog sent a letter today to ... to make health care affordable and available by allowing ... group warned Obama that a proposal pushed by health ... health insurance policies "amounts only to a government-funded customer ...
... Costs as Key , , WASHINGTON, ... Excellence report looks at how states are balancing retiree health care ... , Retiree Health Care in the American States ... care benefits to central human resources (HR) goals; how the states ...
... Diagnostics Incorporated (NYSE: DGX ), the world,s leading ... is scheduled to speak at the Piper Jaffray Healthcare Conference ... Quest Diagnostics presentation is scheduled to begin at 4:00 p.m. ... During the conference, the company will reaffirm its 2008 ...
... Patients treated with radiation prior to surgery for ... and better overall survival rates, according to a recent ... neoadjuvant therapy, which can reduce cancerous tumor size or ... the tumor. Neoadjuvant therapy may include chemotherapy and/or radiation. ...
... probably higher with aprotinin, a drug commonly used to control ... analogues, according to a study http://www.cmaj.ca//cgi/rapidpdf/cmaj.081109 to be ... , On December 3, a Health Canada expert advisory ... is being early released in advance of the meeting. ...
Cached Medicine News:Health News:VirtualScopics Backlog Rises to a Record $27 Million 2Health News:VirtualScopics Backlog Rises to a Record $27 Million 3Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 3Health News:States View Limits on Retiree Health Benefits 2Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2
... automated, wireless, computerized remote temperature monitoring, ... refrigerator, freezer, incubator and water bath ... and manual temperature log reports., The ... and comes complete with installation, training ...
... water for use, it provides ... physically clean hands when routine ... an option or is not ... return to patient care faster, ...
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity....
Medicine Products: